Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

ARNA 4.04 +0.07 (1.76%)
price chart
Zacks Rating on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a hold, according to the latest average broker rating of 2.5. The number of analysts in this rating is 6. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation ...
Arena Pharmaceuticals Upgraded to Hold at Zacks (ARNA)  Dakota Financial News
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Short Interest Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), A drop of 1,185,971 shares or 4% was seen in the short interest of Arena Pharmaceuticals, Inc.. Even as the interest dropped from 29,624,866 shares on June 30,2015 to 28,438,895 shares on July 15,2015, the ...
Stock Update - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Vanguard Tribune
Arena's Phase 2 Trial An Opportunity For Improved Valuation (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) announced today that the company is moving forward with a Phase 2 clinical trial on its drug candidate called APD334.
Arena Pharmaceuticals (ARNA) Showing Signs Of Perilous Reversal Today
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Rating Update  Insider Trading Report
Arena Benefits From Celgene Buyout Of Receptos  Seeking Alpha
12-Month Top Losers in Healthcare: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), latest closing price of $4.08 is at a discount to its 200-day moving average price of $4.47.
Arena Pharmaceuticals Inc (NASDAQ:ARNA) in Spotlight
[EDGAR] Arena Pharmaceuticals Inc (NASDAQ:ARNA)(TREND ANALYSIS) On July 9, 2015, our Board of Directors appointed Jack Lief, our President and Chief Executive Officer, as our principal financial officer, and Jennifer K. Bielasz, our Vice President, ...
Top Biotech Stock Picking - Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX ...  Wall Street Observer
Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 ...
SAN DIEGO, July 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis.
Biotech Stocks Worth Chasing - Amicus Therapeutics, Inc. (NASDAQ:FOLD), Arena ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose +0.25% to end last trading session at $4.09. The company, on July 29, 2015, released the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis ...
Will Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surprise Analysts?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is next slated to report earnings for the current quarter on 2015-08-07. Brokerages covering the stock are currently expecting the firm to earn $-0.15 per share based on the 4 covering brokerages weighted into ...
Arena Pharmaceuticals Rating Increased to Hold at Zacks (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) traded up 1.51% on Wednesday, reaching $4.03. The company's stock had a trading volume of 347,726 shares.
Arena Pharmaceuticals, (NASDAQ:ARNA), TrueCar (NASDAQ:TRUE),Iron Mountain ...  JBH News